Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amb a 1
- Development stage
- Unknown
- Lead developer
- ALK Abelló
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Sublingual
01
Overview
Amb a 1 is a major allergen protein from short ragweed (Ambrosia artemisiifolia) pollen. It's a pectate lyase enzyme that represents 54-78% of ragweed pollen allergenic molecules and 90% of its allergenic potential. This non-glycosylated protein with a molecular weight of 38 kDa is used as a marker of sensitization to ragweed pollen and as an active component in allergen immunotherapy products for treating ragweed allergies.
- Other names
- Amb a IAmb e 1a24a-24a 24a789a-789a 789AgEAmb a 1-likeAntigen EPectate Lyasew230w-230w 230
02
Targets
Immunoglobulin E specific for Amb a 1MHC II (Major histocompatibility complex class II receptor)TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on Amb a 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amb a 1.